Terumo Blood and Cell Technologies

Frustrated with fill and finish steps slowing your cell therapy manufacturing process? You may be interested in this new research conducted by Charles River Laboratories. It showed that the Finia Fill and Finish System can successfully perform four back-to-back runs to process a harvest of T cells. Dose accuracy and cell concentration were maintained across the sequential runs, as was cell health, including viability, functionality, and phenotype. In the study, 12 product bags were completed in about 2 hours with a 60% reduction in hands-on labor. Explore the full study results here: https://bit.ly/4cH7qAt #Finia #celltherapy #biomanufacturing #finalformulation #CAR-T #CGT

Are you good at trivia? Well, let’s see. Fill in the blank by putting your answer in the comment section below! “At Terumo Blood and Cell Technologies, we serve patients in _____countries around the world .” In our previous #FunFactFriday series we shared our journey on expanding our product line from perfusion and dialysis, to blood processing. With this growth, came also a need to expand our network globally. In 1973, we opened our first office outside of the U.S., in Zaventem, Belgium. By 1988, subsidiaries were set up in England, Italy, Japan, Australia and more, allowing us to serve more patients. In 2011, we were acquired by Terumo Corporation, a global medtech company headquartered in Tokyo. Today, we are an integral part of Terumo Group’s portfolio, representing one of the three companies. We serve patients in 150+ countries with the help and contribution of 400+ distributors and 8,000 associates – all playing their part in realizing our mission of Contributing to Society through Healthcare. Now, back to the trivia section. Did you put your answer in the comment section, yet? Stay tuned for our final #FunFactFriday 60th Anniversary post next week so you don’t miss out on the celebrations. #TerumoProud #60WaysFor60Years #LakewoodCO #DropOfHope

Meet Mariah Jacqueline Scott, M.S., M.P.H, a remarkable 32-year-old who battles sickle cell disease and recently achieved her dream of becoming a mother. In our latest video, Mariah shares her journey of resilience and triumph. This inspiring film, produced in collaboration with Terumo Blood and Cell Technologies, highlights the ongoing research and support for those with #sicklecell, especially during pregnancy. As we share this directly here on LinkedIn, we hope Mariah's story continues to spread hope and encouragement to many. Whether you've seen her journey before or are viewing it for the first time, Mariah's strength and perseverance will inspire you. Join the conversation and share your thoughts on Mariah's journey below! #SCD #WSCD #HopeThroughProgress #TerumoProud Film by: Cameron Kit

Last chance to register 📢 We are proud to co-host the webinar “Empowering Lifesavers: Innovations in Blood Donor Recruitment and Retention” with ADRP: The Association for Blood Donor Professionals. Don’t miss out on this opportunity to hear from diverse perspectives on donor recruitment and retention. We will connect blood center professionals and frequent blood donors, to lead discussions on how to overcome challenges in sustaining the blood supply. 🩸Speakers: - Anand Deshpande from P.H. Hinduja Hospital, India - Luxi Zhang, a frequent blood donor and donor advocate from China - Theresa Pina from Gulf Coast Regional Blood Center in the U.S. - Prakash Menon from the Singapore Red Cross Reserve your place here today: https://lnkd.in/gYDu8yKC #BloodDonation #DonorRecruitment #BloodSupply #BloodAdvocacy

Monisha Obrecht Terumo Blood and Cell Technologies #LeadershipJeffco40 We're thrilled to welcome a new member to this year's 40th Leadership Jeffco class! Monisha immigrated to the US as a child and grew up in Pueblo, Colorado. She holds a bachelor's degree in Mechanical Engineering from Colorado School of Mines and a master's degree in Mechanical Engineering from Purdue University. Monisha is a wife and mother of 3 college aged children. She is currently the Senior Manager at Terumo Blood and Cell Technologies in the Global Services organization.

Reimbursement policies support access to healthcare services, as well as the development of innovative healthcare technologies and novel therapies, such as CAR-T therapy. We encourage stakeholders to submit comments to the Centers for Medicare and Medicaid Services (CMS) to advocate for outpatient CAR-T cell collection and processing clinical services. The deadline is this September 9. CMS has released the Calendar Year 2025 proposed rules for the Outpatient Prospective Payment System (OPPS) and the Medicare Physician Fee Schedule (MPFS). Our company supports the MPFS proposal to replace Category III codes with permanent Category I codes because we recognize it as a separate medical procedure. This has been nearly universally supported by the major stakeholders. Practically, this should lead to additional reimbursement opportunities for those performing the collection, which is especially important in the event of repeat collections and collections that do not result in the administration of finished CAR-T cell therapies. The OPPS proposal suggests bundling the harvesting of blood-derived T lymphocytes (3X018) with the preparation and transportation of CAR-T cells for administration (3X019, 3X020) while keeping the administration of CAR-T cells (3X021) separate. We do not support this bundling. We believe cell collection, transport, and processing should be recognized as distinct clinical services, each deserving separate reimbursement. Comments can be submitted here: OPPS (https://lnkd.in/gsdnTEgz) and MFPS (https://lnkd.in/gs-qcpvw) Read more here ➡️ https://bit.ly/3AH8TcU

In the rapidly evolving biopharmaceutical landscape, the World Health Organization's Model List of Essential Medicines continues to grow. However, this expansion highlights a critical challenge: the widening gap in global access to needed treatments. Trevor Smith, Senior Manager, Regional Marketing - Cell & Gene Therapy at Terumo Blood & Cell Technology, shares insights into how strategies such as IP licensing and knowledge transfers are making a difference. From the success of CAR-T therapies in China to India's NexCAR19, efforts to decentralize and innovate are paving the way for improved patient access to treatments. Read more to learn how the industry is tackling these challenges and striving for equitable healthcare solutions for all:   How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle? (https://lnkd.in/eBD8nppK) How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications? (https://lnkd.in/eNBRuuzb) #InnovationandQuality #CellTherapy #GlobalHealth #TerumoBCT  

Terumo Blood and Cell Technologies recently received a "Workforce Champion Award" from Metropolitan State University of Denver. The company's dedication to fostering strong industry-academia partnerships has been instrumental in connecting graduates with local #jobopportunities. "Our team has been actively involved in developing a Workforce Playbook as a member of the MSU Industry Partnership Advisory Board," said Nathan Frank, Laboratory Scientist 4 at Terumo BCT, who accepted the award. "This playbook aims to streamline the job-matching process by connecting graduates with local industry leaders." Terumo BCT has a longstanding commitment to supporting educational initiatives. The company maintains strong relationships with numerous #Colorado universities through its internship program. The Workforce Playbook offers valuable resources for both new graduates and companies seeking to hire recent talent. "Terumo BCT's informal Intern Council, led by former interns, plays a vital role in overseeing the company's internship activities," said Miguel Garcia Jara, a Terumo BCT engineer. "We are dedicated to providing students with meaningful experiences, including campus tours and visits to our Research & Development areas." He is a former intern who started at Terumo BCT in 2021 after receiving a degree in chemical engineering from the University of Colorado at Boulder. Terumo BCT is grateful for this recognition from Metro State University of Denver and remains committed to fostering a strong workforce pipeline. #TerumoProud #WorkforceDevelopment

Happy #FunFactFriday At Terumo Blood and Cell Technologies, innovation is at the core of everything we do. We have been committed to advancing patient care through technology innovations for six decades. After COBE was founded in 1964, our journey took off to new levels with the acquisition and development of key technologies in three main fields: cardiovascular surgery, dialysis and blood processing. Many of our current devices and technologies have their roots in the pioneering work from this early period. By the mid-1970s, our rapid growth—doubling in size every two years—highlighted our drive for innovation. New products were regularly introduced: dialyzers, dialysis machines, membrane oxygenators and more. Entry into the blood component technology industry started in 1978 when we first developed the Centry TPE membrane system for therapeutic plasma exchange. Through acquisitions and the development of new technologies, we continued to expand our impact. One milestone was the launch of the COBE Spectra Apheresis System in 1988. The system allowed various procedures that required blood component separation. For example, it enabled the collection of platelets from a single donor and the transfusing of the platelets to a cancer patient undergoing chemotherapy. Celebrate with us as we remember our innovation journey, and stay tuned for more insights on how we’re continuing to push the boundaries of patient care! #TerumoProud #60WaysFor60Years #LakewoodCO #DropOfHope #RandD #PatientCare #MedicalInnovation #Apheresis #TPE

It's #ThrowbackThursday 📻 Tune in to this BioInsights podcast from last August, where Dr. Dalip Sethi, PhD, MBA, Commercial Leader, Cell Therapy Technologies, shares his insights on the various factors when choosing a cell culture media. https://bit.ly/3MgSpe1 Key takeaway? The best culture conditions comes from the combination of the right bioreactor and media composition. Getting the right phenotype and number of cells, allowing a cell therapy manufacturer to be able to dose a particular patient or clinical trial participant in the right way is important. #CellTherapy #CGT #CellCulture #CellTherapyManufacturer